177276-40-3

Usage

Uses

Used in Pharmaceutical Research:
Benzyl 4-(1-(tert-butoxycarbonyl)piperidin-4-yl)piperazine-1-carboxylate serves as a valuable building block for the synthesis of potential drug candidates. Its unique structure and properties make it a promising component in the development of new medications.
Used in Medicinal Chemistry:
In the realm of medicinal chemistry, benzyl 4-(1-(tert-butoxycarbonyl)piperidin-4-yl)piperazine-1-carboxylate is employed for its potential to contribute to the creation of novel therapeutic agents. Its specific structural features allow it to be a key constituent in the design and synthesis of pharmaceutical compounds.
Used in Chemical Research:
Beyond its applications in medicine, benzyl 4-(1-(tert-butoxycarbonyl)piperidin-4-yl)piperazine-1-carboxylate may also find use in broader chemical research. Its distinctive attributes could be harnessed in various chemical processes and reactions, expanding its utility across different scientific disciplines.
Safety Precautions:
It is crucial to handle and store benzyl 4-(1-(tert-butoxycarbonyl)piperidin-4-yl)piperazine-1-carboxylate with appropriate safety measures. Due to its complex nature, mishandling of benzyl 4-(1-(tert-butoxycarbonyl)piperidin-4-yl)piperazine-1-carboxylate could result in hazards, necessitating careful management and adherence to safety protocols during its use in research and development.

Upstream product

• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 501-53-1 benzyl chloroformate 
• 31166-44-6 phenylmethyl 1-piperazinecarboxylate 

Downstream Products

• 177276-41-4 4-(piperazin-1-yl)piperidine-1-carboxylic acid tert-butyl ester 
• 688020-80-6 4-(4-piperidinyl)-1-piperazinecarboxylic acid,phenylmethyl ester 
• 928038-54-4 benzyl 4-{1-[4-(3-fluoro-4-{[1-(4-fluorophenylcarbamoyl)cyclopropanecarbonyl]amino }phenoxy)pyridin-2-ylcarbamoyl]piperidin-4-yl}piperazine-1-carboxylate 
• 1477815-42-1 4-{4-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3-trifluoromethoxyphenylcarbamoyl]piperazin-1-yl}piperidine-1-carboxylic acid tert-butyl ester 
• 1477815-41-0 4-[4-(4-bromo-3-trifluoromethoxyphenylcarbamoyl)piperazin-1-yl]piperidine-1-carboxylic acid tert-butyl ester 
• 1477815-33-0 4-[4-(4-bromo-2-chloro-5-trifluoromethoxyphenylcarbamoyl)piperazin-1-yl]piperidine-1-carboxylic acid tert-butyl ester 
• 1477816-43-5 {(S)-2-methyl-1-[(2S,4S)-4-methyl-2-(7-{4-[(4-(piperidin-4-yl)piperazine-1-carbonyl)amino]-2-trifluoromethoxyphenyl}-3H-naphtho[1,2-d]imidazol-2-yl)pyrrolidine-1-carbonyl]propyl}carbamic acid methyl ester 
• 1477816-38-8 {(S)-1-[(2S,4S)-4-methoxy-2-(4-{4'-[(4-(piperidin-4-yl)piperazine-1-carbonyl)amino]-2'-trifluoromethoxybiphenyl-4-yl}-1H-imidazol-2-yl)pyrrolidine-1-carbonyl]-2-methylpropyl}carbamic acid methyl ester 

Relevant academic research and scientific papers

Compound used as ALK (anaplastic lymphoma kinase) inhibitor and application thereof

The invention discloses a compound shown in a formula I, and pharmaceutically acceptable salts, stereoisomers, solvates or predrugs. The symptoms are defined in claim requirements. The compound shownin the formula I has good inhibiting activity on ALK (anaplastic lymphoma kinase), and can be used for preparing medicines for adjusting the activity of the ALK activity or treating the ALK-related diseases, especially nonsmall-cell lung cancer drugs. (The formula I is shown in the attached figure.).

PIPERAZINE-PIPERIDINE COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS

The invention provides compounds of formula (I): wherein the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are inhibitors of replication of the hepatitis C virus. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat hepatitis C viral infections, and processes and intermediates useful for preparing such compounds.

NOVEL PYRIDINE DERIVATIVE AND PYRIMIDINE DERIVATIVE (3)

A compound represented by the following formula, a salt thereof or a hydrate of the foregoing has an excellent hepatocyte growth factor receptor (HGFR) inhibitory activity, and exhibits anti-tumor activity, angiogenesis inhibitory activity and cancer metastasis inhibitory activity. [R1 represents a 3- to 10-membered non-aromatic heterocyclic group or the like; R2 and R3 represent hydrogen; R4, R5, R6, and R7 may be the same or different and each represents hydrogen, halogen, C1-6 alkyl or the like; R8 represents hydrogen or the like; R9 represents a 3- to 10-membered non-aromatic heterocyclic group or the like; n represents an integer of 1 or 2; X represents -CH=, nitrogen or the like.]

SUBSTITUTED BENZIMIDAZOLONE DERIVATIVES, MEDICAMENTS COMPRISING THEM AND THEIR USE

The present invention relates to novel benzimidazolone derivatives of the general formula (I) in which the substituents R1, R2, R3, A1, A2, and B are as defined in claim 1, medicaments comprising these, and the use thereof for the prophylaxis and/or treatment of vasopressin-dependent diseases.

Imidazopyridine Kinase Inhibitors

The present invention provides imidazopyridine compounds, compositions containing the same, as well as processes for the preparation and methods for their use as pharmaceutical agents.

Benzenesulphonamide derivatives, method for production and use thereof for treatment of pain

The present invention concerns novel benzenesulphonamide compounds, defined by formula I and the description, their method of preparation and their use in therapy.

Compounds with platelet aggregation inhibitor activity

A compound represented by the general formula (I) and a pharmaceutically acceptable salt and solvate thereof having an effect for inhibiting the aggregation of platelets is disclosed: STR1 wherein A, B and C represent independently CH2 or C=O;